{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:08:41Z","timestamp":1790809721917,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1002\/hep.29672","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T01:16:51Z","timestamp":1511140611000},"page":"89-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":144,"title":["New insights into diagnosis and therapeutic options for proliferative hepatoblastoma"],"prefix":"10.1097","volume":"68","author":[{"given":"Katarzyna B.","family":"Hooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Audoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lesjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ernault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dugot\u2010Senant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leste\u2010Lasserre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Danet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Branchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brugi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Taque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Annick","family":"Buendia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Commes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe F.","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Aur\u00e9lie","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20241017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MOP.0000000000000046","article-title":"Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy","volume":"26","author":"Czauderna","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"R2-18-20241017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk\u2010stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic Tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol"},{"key":"R3-18-20241017","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0959-8049(00)00074-5","article-title":"Pretreatment prognostic factors for children with hepatoblastoma\u2014results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1","volume":"36","author":"Brown","year":"2000","journal-title":"Eur J Cancer"},{"key":"R4-18-20241017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0971-9261.142001","article-title":"The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials","volume":"19","author":"Aronson","year":"2014","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"R5-18-20241017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00247-006-0361-5","article-title":"2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group","volume":"37","author":"Roebuck","year":"2007","journal-title":"Pediatr Radiol"},{"key":"R6-18-20241017","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejca.2007.11.022","article-title":"Hepatoblastoma with a low serum alpha\u2010fetoprotein level at diagnosis: the SIOPEL group experience","volume":"44","author":"De Ioris","year":"2008","journal-title":"Eur J Cancer"},{"key":"R7-18-20241017","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ejca.2011.10.019","article-title":"Potential biomarkers for hepatoblastoma: results from the SIOPEL\u20103 study","volume":"48","author":"Purcell","year":"2012","journal-title":"Eur J Cancer"},{"key":"R8-18-20241017","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem\u2010like phenotype and interplay of Wnt\/beta\u2010catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Cairo","year":"2008","journal-title":"Cancer Cell"},{"key":"R9-18-20241017","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"key":"R10-18-20241017","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","article-title":"Activation of beta\u2010catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice","volume":"147","author":"Tao","year":"2014","journal-title":"Gastroenterology"},{"key":"R11-18-20241017","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/hep.27243","article-title":"Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex","volume":"60","author":"Jia","year":"2014","journal-title":"Hepatology"},{"key":"R12-18-20241017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1756-9966-30-96","article-title":"HGF\/c\u2010Met related activation of beta\u2010catenin in hepatoblastoma","volume":"30","author":"Purcell","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"R13-18-20241017","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s003830000576","article-title":"High frequency of beta\u2010catenin mutations in hepatoblastoma","volume":"17","author":"Udatsu","year":"2001","journal-title":"Pediatr Surg Int"},{"key":"R14-18-20241017","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jhep.2014.09.016","article-title":"Unravelling the genetics of hepatoblastoma: few mutations, what else?","volume":"61","author":"Buendia","year":"2014","journal-title":"J Hepatol"},{"key":"R15-18-20241017","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jhep.2014.08.009","article-title":"The genomic landscape of hepatoblastoma and their progenies with HCC\u2010like features","volume":"61","author":"Eichenmuller","year":"2014","journal-title":"J Hepatol"},{"key":"R16-18-20241017","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/emboj.2012.126","article-title":"Drugging Wnt signalling in cancer","volume":"31","author":"Polakis","year":"2012","journal-title":"EMBO J"},{"key":"R17-18-20241017","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep4.1029","article-title":"MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta\u2010catenin and Wnt signaling","volume":"1","author":"Indersie","year":"2017","journal-title":"Hepatol Commun"},{"key":"R18-18-20241017","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/gb-2013-14-3-r30","article-title":"CRAC: an integrated approach to the analysis of RNA\u2010seq reads","volume":"14","author":"Philippe","year":"2013","journal-title":"Genome Biol"},{"key":"R19-18-20241017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"R20-18-20241017","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA\u2010seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"R21-18-20241017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: an R package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J Stat Soft"},{"key":"R22-18-20241017","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge\u2010based approach for interpreting genome\u2010wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-18-20241017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-016-0510-x","article-title":"ITGA6 is directly regulated by hypoxia\u2010inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models","volume":"15","author":"Brooks","year":"2016","journal-title":"Mol Cancer"},{"key":"R24-18-20241017","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s004120050393","article-title":"Meiotic events at the centromeric heterochromatin: histone H3 phosphorylation, topoisomerase II alpha localization and chromosome condensation","volume":"108","author":"Cobb","year":"1999","journal-title":"Chromosoma"},{"key":"R25-18-20241017","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1038\/cddis.2013.347","article-title":"Epithelial\u2013mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease","volume":"4","author":"Li","year":"2013","journal-title":"Cell Death Dis"},{"key":"R26-18-20241017","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ccr.2014.06.018","article-title":"Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models","volume":"26","author":"Nguyen","year":"2014","journal-title":"Cancer Cell"},{"key":"R27-18-20241017","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/pbc.24024","article-title":"DLK1, a serum marker for hepatoblastoma in young infants","volume":"59","author":"Falix","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R28-18-20241017","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial\u2013mesenchymal transitions","volume":"119","author":"Zeisberg","year":"2009","journal-title":"J Clin Invest"},{"key":"R29-18-20241017","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/jcm4121958","article-title":"Epithelial\u2010to\u2010mesenchymal transition and cancer invasiveness: what can we learn from cholangiocarcinoma?","volume":"4","author":"Brivio","year":"2015","journal-title":"J Clin Med"},{"key":"R30-18-20241017","first-page":"211","article-title":"Genetic analysis of Runx2 function during intramembranous ossification","volume":"143","author":"Takarada","year":"2016","journal-title":"Development"},{"key":"R31-18-20241017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1359\/JBMR.040812","article-title":"Cell\u2013cell interaction mediated by cadherin\u201011 directly regulates the differentiation of mesenchymal cells into the cells of the osteo\u2010lineage and the chondro\u2010lineage","volume":"19","author":"Kii","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R32-18-20241017","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"R33-18-20241017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.14348\/molcells.2015.0175","article-title":"Exploiting the Fanconi anemia pathway for targeted anti\u2010cancer therapy","volume":"38","author":"Jo","year":"2015","journal-title":"Mol Cells"},{"key":"R34-18-20241017","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1186\/s13058-014-0474-y","article-title":"Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large\u2010scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia","volume":"16","author":"Spurdle","year":"2014","journal-title":"Breast Cancer Res"},{"key":"R35-18-20241017","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.chembiol.2011.08.014","article-title":"Selective and cell\u2010active inhibitors of the USP1\/ UAF1 deubiquitinase complex reverse cisplatin resistance in non\u2010small cell lung cancer cells","volume":"18","author":"Chen","year":"2011","journal-title":"Chem Biol"},{"key":"R36-18-20241017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1541-7786.MCR-11-0497","article-title":"Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross\u2010linking agents","volume":"10","author":"Kee","year":"2012","journal-title":"Mol Cancer Res"},{"key":"R37-18-20241017","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1158\/0008-5472.CAN-07-1015","article-title":"Proteasome function is required for DNA damage response and fanconi anemia pathway activation","volume":"67","author":"Jacquemont","year":"2007","journal-title":"Cancer Res"},{"key":"R38-18-20241017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","article-title":"Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels","volume":"91","author":"Baiz","year":"2009","journal-title":"Biochimie"},{"key":"R39-18-20241017","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00535-012-0675-z","article-title":"Bortezomib induces tumor\u2010specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis","volume":"48","author":"Saeki","year":"2013","journal-title":"J Gastroenterol"},{"key":"R40-18-20241017","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10495-007-0063-y","article-title":"SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor bortezomib","volume":"12","author":"Emanuele","year":"2007","journal-title":"Apoptosis"},{"key":"R41-18-20241017","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.2741\/e536","article-title":"Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells","volume":"4","author":"Armeanu\u2010Ebinger","year":"2012","journal-title":"Front Biosci (Elite Ed"},{"key":"R42-18-20241017","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B\u2010precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"key":"R43-18-20241017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrm.2016.48","article-title":"The Fanconi anaemia pathway: new players and new functions","volume":"17","author":"Ceccaldi","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R44-18-20241017","doi-asserted-by":"crossref","first-page":"e1005563","DOI":"10.1371\/journal.pgen.1005563","article-title":"FANCI regulates recruitment of the FA core complex at sites of DNA damage independently of FANCD2","volume":"11","author":"Castella","year":"2015","journal-title":"PLoS Genet"},{"key":"R45-18-20241017","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high\u2010risk hepatoblastoma with dose\u2010intensive multiagent chemotherapy and surgery: final results of the SIOPEL\u20103HR study","volume":"28","author":"Zsiros","year":"2010","journal-title":"J Clin Oncol"},{"key":"R46-18-20241017","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1093\/nar\/gks670","article-title":"Repair of cisplatin\u2010induced DNA interstrand crosslinks by a replication\u2010independent pathway involving transcription\u2010coupled repair and translesion synthesis","volume":"40","author":"Enoiu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"R47-18-20241017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-11-26","article-title":"Non\u2010specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin","volume":"11","author":"Jacquemont","year":"2012","journal-title":"Mol Cancer"},{"key":"R48-18-20241017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"R49-18-20241017","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","article-title":"Phase II study of first\u2010line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end\u2010point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur J Cancer"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29672","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201807000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:43:21Z","timestamp":1729194201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201807000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29672","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}